Last reviewed · How we verify
NCT07384884: SLITT-GBM
Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas
NA trial testing surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines in Brain Tumours in 12 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | King's College Hospital NHS Trust |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 March 2026 |
| Primary completion | 31 December 2026 |
| Estimated completion | 1 July 2027 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
Conditions studied
- Brain Tumours — all drugs for Brain Tumours →
- GBM — all drugs for GBM →
Sponsor
King's College Hospital NHS Trust
Who can join
Adults 18 to 80, any sex, with Brain Tumours or GBM. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Butterfly glioblastomas (bGBM), defined as tumours crossing the midline to involve hemispheres bilaterally, have a dismal prognosis with a median survival of 3.3-6 months and only 9% of patients with bGBM survive 2-years. These figures put bGBM in the worst end of the spectrum of GBM prognosis, significantly inferior to the survival figures quoted in the literature with standard of care - 14.6 months - particularly when 5-aminolevulinic acid is used as surgical adjuvant - 17.47 months. Despite the poor outcome of this disease, there is preliminary evidence suggesting that active oncology treatment can impact the survival of patients with this condition.With particular regards to surgical resection versus biopsy, there is a suggestion that resection improves overall survival at 6 months with no clear difference at 12 and 18 months of follow up. Laser-induced thermal therapy (LITT) is a minimally invasive laser ablation technique used in a range of brain tumours, including glioblastomas, with similar overall survival to the ones reported for open surgery in patients with lesions not amenable to open resection. The minimally invasive nature of this technique, significantly reducing the collateral damage to the surrounding brain structures, suggests Its potential in the treatment of this bGBM \[14\] with significant implications as a deficit-sparing technique, particularly if associated with preoperative and intraoperative monitoring and mapping techniques. The SLITT-GBM study will combine unilateral open surgery for maximal tumour resection with contralateral LITT to the smaller component/residual.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07384884
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
Trials testing the same drug.
- NCT07078435 — Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis · NA · not yet recruiting
- NCT06810609 — Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC · Phase 2 · recruiting
- NCT06960889 — A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients · active not recruiting
- NCT07114497 — Investigation of miRNA Expression Profiles in Human Degenerated Intervertebral Disc Tissues · NA · active not recruiting
- NCT07264647 — Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
Other recruiting trials for Brain Tumours
Currently open trials in the same condition.
- NCT07140601 — Environmental Pollutants and Neurological Disorders · recruiting
- NCT06951659 — Investigating Visual Verticality Disorder and Lateropulsion in a Neurosurgical Cohort of Patients With Brain Tumours · recruiting
- NCT06835426 — High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins · NA · recruiting
Other King's College Hospital NHS Trust trials
Trials by the same sponsor.
- NCT07379723 — Brief Intervention for FCD: A Feasibility Study · NA · recruiting
- NCT07062731 — Pelvic Floor Exercises for Suboptimal Anorectal Manometry · recruiting
- NCT06766162 — Virtual Reality to Improve Patient Experience During Endoscopic Mucosal and Submucosal Resection · NA · completed
- NCT06918756 — Development of a Cough Control Questionnaire (CCQ) · recruiting
- NCT07083908 — A Comparison of THD® Anopress With High Resolution Anorectal Manometry · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07384884 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King's College Hospital NHS Trust
- Last refreshed: 19 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07384884.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing